Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM2 | Q9P1W9 | 5/20 | 0.39 |
| ▸ | PIM1 | P11309 | 5/20 | 0.39 |
| ▸ | PIM3 | Q86V86 | 3/20 | 0.39 |
| ▸ | RET | P07949 | 2/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12991467 | 1.00 | PIM2 (0.39) | PIM2PIM1PIM3RETCHRNA7 | |
| SCHEMBL12991345 | 0.90 | TSHR (0.40) | PIM2PIM1RETKDM4EALDH1A1 | |
| SCHEMBL3527295 | 0.90 | TSHR (0.40) | PIM2PIM1RETKDM4EALDH1A1 | |
| SCHEMBL3532230 | 0.88 | DPP4 (0.38) | PIM2RETKDM4EALDH1A1HSD17B10 | |
| SCHEMBL12991499 | 0.88 | DPP4 (0.38) | PIM2RETKDM4EALDH1A1HSD17B10 | |
| SCHEMBL12991226 | 0.82 | FAAH (0.47) | RETFAAHDPP4 | |
| SCHEMBL12991231 | 0.82 | ALDH1A1 (0.41) | RETCHRNA7KDM4EALDH1A1HSD17B10 | |
| SCHEMBL3535125 | 0.82 | FAAH (0.47) | RETFAAHDPP4 | |
| SCHEMBL3528677 | 0.81 | PIM1 (0.42) | PIM2PIM1PIM3KDM4EALDH1A1 | |
| SCHEMBL12991336 | 0.80 | FAAH (0.47) | RETKDM4EALDH1A1HSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858786-B2 | Pyrimidines and pyrazines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCOROPATED (US) | 2010-12-28 | — | — | US | disclosed |
| US-20070093454-A1 | Pyrimidines and pyrazines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093454-A1 | Pyrimidines and pyrazines useful as modulators of ion channels | KCNJ1, KCNJ2, KCNJ11 | PIM2 3403/4885PIM1 3802/4885PIM3 3557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.